A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE) (ENSEMBLE)
An Open-Label, Phase 3 Long-Term Extension (LTE) Study To Assess The Safety, Tolerability, And Efficacy Of Treatment With Pegtibatinase In Participants With Classical Homocystinuria (HCU) Due To Cystathionine Beta Synthase Deficiency (ENSEMBLE)
The goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of blinded treatment in the Phase 3 HARMONY are eligible to participate.
Participants will be in this clinical study for a minimum of 108 weeks including:
a treatment period of up to 104 weeks a 4-week safety follow-up period
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Overall Design:
This is a global, multicenter, single-arm, open-label study. Participants who meet all eligibility criteria may transition from other pegtibatinase studies and enroll into this LTE study for long-term safety, efficacy, and clinical assessments of pegtibatinase treatment.
All participants will follow a protocol of self-administration of pegtibatinase unless exempted. During the study, pegtibatinase pharmacokinetic assessments will be conducted. An optional protein tolerance modification (PTM) sub-study will also be conducted for eligible participants.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia
- Royal Adelaide Hospital
-
Parkville, Australia
- Royal Children's Hospital Melbourne
-
Westmead, Australia
- Westmead Hospital
-
-
-
-
-
Brussels, Belgium
- Cliniques Universitaires Saint-Luc
-
Edegem, Belgium
- Universitair Ziekenhuis Antwerpen (UZA)
-
-
-
-
-
Paris, France
- Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades
-
Tours, France
- CHRU Hôpitaux de Tours - Hôpital Bretonneau
-
Vandœuvre-lès-Nancy, France
- Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants
-
-
-
-
-
Hamburg, Germany
- Universitätsklinikum Hamburg-Eppendorf
-
Leipzig, Germany
- Universitätsklinikum Leipzig
-
Münster, Germany
- Universitätsklinikum Münster
-
-
-
-
-
Dublin, Ireland
- Children's Health Ireland (CHI) at Temple Street
-
-
-
-
-
Bari, Italy
- Ospedale Pediatrico Giovanni XXIII
-
Genova, Italy
- IRCCS Istituto Giannina Gaslini
-
Milan, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)
-
Monza, Italy
- Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo
-
Padova, Italy
- Azienda Ospedaliera di Padova
-
-
-
-
-
Krakow, Poland
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Warsaw, Poland
- Instytut Matki i Dziecka
-
Warsaw, Poland
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
-
-
-
-
Coimbra, Portugal
- Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra
-
Lisbon, Portugal
- Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria
-
Porto, Portugal
- Unidade Local de Saúde de São João, EPE - Hospital São João
-
-
-
-
-
Doha, Qatar
- Hamad General Hospital
-
Doha, Qatar
- Sidra Hospital
-
-
-
-
-
Riyadh, Saudi Arabia
- King Abdullah International Medical Research Center
-
Riyadh, Saudi Arabia
- King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh
-
-
-
-
-
Barcelona, Spain
- Hospital Sant Joan de Déu
-
Madrid, Spain
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Hospital Universitario Ramón y Cajal
-
Santiago de Compostela, Spain
- Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario
-
Seville, Spain
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Ankara, Turkey (Türkiye)
- Gazi University Hospital
-
Bornova, Turkey (Türkiye)
- Ege Üniversitesi Hastanesi Bornova
-
Istanbul, Turkey (Türkiye)
- Istanbul University Cerrahpasa Hospital
-
-
-
-
-
Birmingham, United Kingdom
- Birmingham Women's and Children's NHS Foundation Trust
-
Birmingham, United Kingdom
- University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
-
London, United Kingdom
- University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery
-
Salford, United Kingdom
- Salford Royal NHS Foundation Trust - Salford Royal Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Phoenix Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University School of Medicine
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Maine
-
Portland, Maine, United States, 04012
- Maine Health Pediatric Specialty Care
-
-
Maryland
-
Chevy Chase, Maryland, United States, 20815
- Uncommon Cures
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
North Carolina
-
Morrisville, North Carolina, United States, 27560
- Science 37 - Virtual Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15224
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Utah Health - The University of Utah Primary Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Participants active in the COMPOSE study or who completed the 24- week blinded period on study intervention (pegtibatinase or placebo) in the Phase 3 HARMONY study
Exclusion Criteria:
• Participant permanently discontinued from study intervention treatment in a previous pegtibatinase study due to serious AE (SAE) or intolerance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: pegtibatinase
|
Pegtibatinase BIW
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment-emergent AEs
Time Frame: Week 1 - Week 108
|
Incidence of treatment-emergent AEs |
Week 1 - Week 108
|
|
Hypermethioninemia
Time Frame: Week 1 - Week 108
|
Incidence of hypermethioninemia |
Week 1 - Week 108
|
|
Hypomethioninemia
Time Frame: Week 1 - Week 108
|
Incidence of hypomethioninemia |
Week 1 - Week 108
|
|
Dietary Protein Rescue
Time Frame: Week 1 - Week 108
|
Proportion of participants requiring dietary protein rescue for participants with hypomethioninemia |
Week 1 - Week 108
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Drug Concentration
Time Frame: Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
Pegtibatinase pharmacokinetic parameters at steady state - maximum drug concentration [Cmax] |
Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
|
Area under the Curve within the Dosing Interval
Time Frame: Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
Pegtibatinase pharmacokinetic parameters at steady state within the - area under the curve within the dosing interval [AUC0-tau] |
Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
|
Total Homocysteine (tHcy) Levels
Time Frame: Week 1 - Week 108
|
Relative and absolute changes from baseline in tHcy levels |
Week 1 - Week 108
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Michael Imperiale, MD, Travere Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Connective Tissue Diseases
- Brain Diseases, Metabolic, Inborn
- Brain Diseases, Metabolic
- Amino Acid Metabolism, Inborn Errors
- Hyperhomocysteinemia
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Skin and Connective Tissue Diseases
- Homocystinuria
Other Study ID Numbers
Other Study ID Numbers
- TVTX-TVT058-302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
IPD Sharing Time Frame
Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.
IPD Sharing Access Criteria
Requires submission and approval of intended use and a data sharing agreement.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.